The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $89.38

Today's change-0.07 -0.08%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $89.38

Today's change-0.07 -0.08%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc down slightly

Biomarin Pharmaceutical Inc closed down just (U.S.)$0.07 Wednesday to (U.S.)$89.38. Over the last five days, shares have gained 5.05% and are currently 2.21% off of the 52-week high. Shares have outperformed the S&P 500 by 12.03% during the last year.

Key company metrics

  • Open(U.S.) $89.55
  • Previous close(U.S.) $89.45
  • High(U.S.) $89.95
  • Low(U.S.) $88.01
  • Bid / Ask-- / --
  • YTD % change+27.05%
  • Volume920,243
  • Average volume (10-day)1,223,542
  • Average volume (1-month)1,121,714
  • Average volume (3-month)1,146,426
  • 52-week range(U.S.) $55.04 to (U.S.) $91.40
  • Beta0.95
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.88
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-18.91%

Biomarin Pharmaceutical Inc has a net profit margin of -18.91%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.77%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue177192152147
Total other revenue--------
Total revenue177192152147
Gross profit147161129122
Total cost of revenue30312325
Total operating expense166211178200
Selling / general / administrative79686071
Research & development1261088697
Depreciation / amortization11112
Interest expense (income), net operating--------
Unusual expense (income)-68103
Other operating expenses, total238-9
Operating income11-20-26-53
Interest income (expense), net non-operating-9-9-9-8
Gain (loss) on sale of assets--------
Other--------
Income before tax3-28-35-59
Income after tax7-34-38-62
Income tax, total-4633
Net income7-34-38-62
Total adjustments to net income--------
Net income before extra. items7-34-38-62
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items7-34-38-62
Inc. avail. to common incl. extra. items7-34-38-62
Diluted net income8-34-38-62
Dilution adjustment000--
Diluted weighted average shares159146144143
Diluted EPS excluding extraordinary itemsvalue per share0.05-0.23-0.26-0.43
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.23-0.23-0.26-0.42